Table 3.
Results after run-in, placebo and montelukast, and difference between randomized treatments.
| Post run-in | Placebo | Montelukast | Difference between montelukast and placebo (95% CI) | |
|---|---|---|---|---|
| Methacholine PD20 (µg) | 63 (15) | 61 (16) | 94 (25)*† | 1.6 fold (1.1, 2.5) |
| FEV1 % predicted | 76 (3) | 71 (3) | 78 (3)* | 7 (3, 12) |
| FEF25-75 % predicted | 42 (3) | 39 (3) | 47 (4)* | 8 (4, 12) |
| Morning PEF (l min−1) | 437 (22) | 419 (22)† | 436 (21)* | 17 (6, 28) |
| Evening PEF (l min−1) | 442 (23) | 426 (22)† | 443 (22)* | 17 (8, 26) |
| Daytime reliever use (puffs) | 1.4 (0.4) | 1.8 (0.4) | 1.0 (0.4)* | 0.8 (0.1, 1.4) |
| Night time reliever use (puffs) | 1.0 (0.6) | 1.6 (0.4) | 0.6 (0.2)* | 0.9 (0.1, 1.8) |
| Daytime symptoms (units) | 0.6 (0.1) | 0.6 (0.1) | 0.3 (0.1)*† | 0.3 (0.1, 0.5) |
| Night time symptoms (units) | 0.5 (0.1) | 0.7 (0.1) | 0.3 (0.1)* | 0.3 (0.1, 0.6) |
Values are shown as means (SE) and mean differences (95% CI) except for methacholine PD20 which is expressed as geometric mean dose (µg) and geometric mean fold difference.
*
Denotes significant (P < 0.05) difference between montelukast vs placebo;
†
denotes significant (P < 0.05) difference from post run-in value.